The FDA has approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for men with phosphatase and tensin homolog (PTEN)-deficient metastatic androgen pathway modulation-naive or sensitive (mAPMN/S) prostate cancer, previously known as metastatic hormone-sensitive prostate cancer. The agency also approved the Ventana PTEN (SP218) RxDx immunohistochemistry assay (Roche) to identify PTEN-deficient patients for treatment. …
Read More
Capivasertib Wins Metastatic Prostate Cancer Approval
